Reply:
Hua Liu, Yonghak Kim, Saul Sharkis, Zhaohui Ye, Yoon‐Young Jang – 26 August 2010
Expanding access to hepatitis C virus treatment—Extension for Community Healthcare Outcomes (ECHO) project: Disruptive innovation in specialty care
Sanjeev Arora, Summers Kalishman, Karla Thornton, Denise Dion, Glen Murata, Paulina Deming, Brooke Parish, John Brown, Miriam Komaromy, Kathleen Colleran, Arthur Bankhurst, Joanna Katzman, Michelle Harkins, Luis Curet, Ellen Cosgrove, Wesley Pak – 26 August 2010 – The Extension for Community Healthcare Outcomes (ECHO) Model was developed by the University of New Mexico Health Sciences Center as a platform to deliver complex specialty medical care to underserved populations through an innovative educational model of team‐based interdisciplinary development.
Novel mechanism of antibodies to hepatitis B virus in blocking viral particle release from cells
Avidan U. Neumann, Sandra Phillips, Idit Levine, Samreen Ijaz, Harel Dahari, Rachel Eren, Shlomo Dagan, Nikolai V. Naoumov – 26 August 2010 – Antibodies are thought to exert antiviral activities by blocking viral entry into cells and/or accelerating viral clearance from circulation. In particular, antibodies to hepatitis B virus (HBV) surface antigen (HBsAg) confer protection, by binding circulating virus.
PNPLeAse get the fats right: Does lipogenesis or lipolysis cause NASH?1
Geoffrey C. Farrell – 26 August 2010
Beta‐blockers in cirrhosis: Friend and foe?
Florence Wong, Francesco Salerno – 26 August 2010
Generation of human induced pluripotent stem cells from liver progenitor cells by only small molecules
Moriguchi Hisashi, Chung Raymond T., Mihara Makoto, Sato Chifumi – 26 August 2010
Bmi1 promotes hepatic stem cell expansion and tumorigenicity in both Ink4a/Arf‐dependent and ‐independent manners in Mice
Tetsuhiro Chiba, Atsuyoshi Seki, Ryutaro Aoki, Hitoshi Ichikawa, Masamitsu Negishi, Satoru Miyagi, Hideyuki Oguro, Atsunori Saraya, Akihide Kamiya, Hiromitsu Nakauchi, Osamu Yokosuka, Atsushi Iwama – 26 August 2010 – We previously reported that forced expression of Bmi1 (B lymphoma Moloney murine leukemia virus insertion region 1 homolog) in murine hepatic stem/progenitor cells purified from fetal liver enhances their self‐renewal and drives cancer initiation.
The “von Meyenburg complex”
Michael Quentin, Axel Scherer – 26 August 2010
Small molecular compounds that inhibit hepatitis C virus replication through destabilizing heat shock cognate 70 messenger RNA
Zong‐Gen Peng, Bo Fan, Na‐Na Du, Yu‐Ping Wang, Li‐Mei Gao, Ying‐Hong Li, Yu‐Huan Li, Fei Liu, Xue‐Fu You, Yan‐Xing Han, Zhi‐Yun Zhao, Shan Cen, Jian‐Rui Li, Dan‐Qing Song, Jian‐Dong Jiang – 26 August 2010 – Host heat shock cognate 70 (Hsc70) protein is packaged into hepatitis C viral (HCV) particles as a structural component of the virus in the assembly process. It helps HCV RNA release into the cytoplasm in the next infection cycle. The goal of this study is to investigate whether chemically down‐regulating host Hsc70 expression could be a novel strategy to interrupt HCV replication.
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection
Andrew J. Muir, Mitchell L. Shiffman, Atif Zaman, Boris Yoffe, Andrew de la Torre, Steven Flamm, Stuart C. Gordon, Paul Marotta, John M. Vierling, Juan Carlos Lopez‐Talavera, Kelly Byrnes‐Blake, David Fontana, Jeremy Freeman, Todd Gray, Diana Hausman, Naomi N. Hunder, Eric Lawitz – 26 August 2010 – Interferon lambda 1 (IFN‐λ1) is a type III IFN that produces intracellular responses similar to those of IFN‐α but in fewer cell types because of differences in the receptor distribution pattern, and this could potentially result in an improved safety profile.